Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from Eli Lilly

A better Ozempic? Eli Lilly’s new obesity drug cut weight by 23%, study finds

In an added benefit, more than one in eight people taking the highest dose of Retratrutide were completely free of arthritic knee pain after 68 weeks

The Independent UK

Eli Lilly CEO David Ricks Unveils $6B Alabama Plant to Produce New Obesity Pill

Eli Lilly CEO David Ricks has announced a new $6 billion manufacturing plant in Alabama dedicated to producing the company's next-generation obesity pill. The move signals Lilly's aggressive expansion as global demand for weight-loss drugs soars.

International Business Times UK

Healthcare Relevancies Clashes With Premium Valuations For Direxion's LLY-Focused ELIL, ELIS ETFs

In terms of sheer relevance, it's difficult to think of a more relevant sector than healthcare — and within this vast ecosystem, only an elite few occupy the same neighborhood as pharmaceutical giant Eli Lilly and Company (NYSE:LLY). In November 2025, Eli Lilly became the first trillion-dollar pharmaceutical company, mostly…

Benzinga

From analysis to the latest developments in health,
read the most diverse news in one place.

Eli Lilly, Pfizer Among 19 Drugs Approved for China's Commercial Health Insurance

China approves 19 innovative drugs for commercial health insurance, opening new market opportunities for global and local drugmakers.

International Business Times

What's Up With The Jump In Viking Therapeutics Stock?

Viking Therapeutics Inc (NASDAQ:VKTX) shares are trading higher on Thursday. The clinical-stage biopharmaceutical company seems to be benefitting from wider excitement in the obesity treatment area, as well as recent positive momentum after major clinical trial developments.

Benzinga

Zepbound 30% Price Cut to $299 Still Far Above Cheaper Overseas Options

Eli Lilly slashes Zepbound to £227 ($299) monthly for US cash payers, but just £31 ($41) in India – though £241 ($319) in Japan.

International Business Times UK

5 Healthcare Names to Watch as Sector Rotation Is in Full Swing

The healthcare sector is outperforming the broader market and tech sector in Q4, confirming a substantial capital shift into the defensive industry.

MarketBeat

Read news from The Economist, FT, and more,
with one subscription

Weight loss drugs go from niche to mainstream

New pricing deals and aggressive marketing are transforming GLP-1s.

Axios

A Conductor For The Orchestra: Seasoned Healthcare Executive Raises $52 Million For An AI Health Startup

Michelle Carnahan has spent the better part of the last three decades working in healthcare at companies like Thirty Madison and Eli Lilly (NYSE:LLY). Now, the entrepreneur has raised $52 million in seed money for her own startup, Arbiter, a platform that connects health care professionals and payers to provide…

Benzinga

Eli Lilly’s Stock Price Has Fattened Up Like a Thanksgiving Turkey. Time to (Options) Collar That Green!

As Eli Lilly makes history by joining the $1 trillion club, here’s how you can position for its next move.

Barchart

The AI Pharma Rally Is Real — And Cancer May Soon Be Chronic, Not Deadly

Pharma stocks have recently emerged as one of Wall Street's hottest trades, with November marking a striking inflection point few had expected.

Benzinga

Healthcare ETFs Trounce Tech, Grab Billions As Big Money Flees Bubble Fears

A powerful rotation into healthcare is taking shape across global markets, with investors pouring money into sector ETFs at one of the fastest clips this year. What started as a cautious move toward defensive stability has quickly morphed into a broader enthusiasm for biotech, pharma and healthcare-services names – helped…

Benzinga

A Trillion-Dollar Pill: Eli Lilly Broke the Healthcare Ceiling

Eli Lilly became the first drugmaker to surpass a trillion-dollar valuation by driving revenue through mass market adoption rather than price increases.

MarketBeat

How Is Eli Lilly’s Stock Performance Compared to Other Pharmaceuticals?

Eli Lilly’s remarkable outperformance within the pharmaceutical sector hasn’t tempered enthusiasm, analysts are still strongly bullish on its long-term growth potential.

Barchart

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

Novo Nordisk's Stock Slump Shows The GLP‑1 Trade's Side Effect: ETF Concentration Risk

Novo Nordisk’s (NYSE:NVO) nearly 11% pre-market drop on Monday and subsequent 9% dip at market open, in the aftermath of disappointing topline results from its evoke/evoke+ Alzheimer’s trials, is more than a pipeline setback. It’s a stress test for healthcare ETFs that have quietly become GLP-1 momentum vehicles. With two…

Barchart

Eli Lilly Stock Just Joined the $1 Trillion Club. Should You Buy LLY Here?

Eli Lilly stock inches higher as the company joins the coveted trillion-dollar club. Citi analysts believe LLY shares will push meaningfully higher in 2026.

Benzinga

3 Weight-Loss Drug Stocks To Consider For 2026

The global weight loss drug market, perhaps ironically, is growing like gangbusters these days. Globally, it’s set to expand from $15 billion in 2024 to $150 billion by 2035, according to Morgan Stanley.

Barchart

Eli Lilly Stock Joins the $1 Trillion Club as LLY Hits New All-Time Highs

Eli Lilly (LLY) just became the first healthcare company to join the $1 trillion market cap club. Shares are trading at a new all-time high on Friday, Nov. 21. The stock is up 40% in the past year and nearly 80% in the past two years. Analysts remain highly confident,...

Get all your
news in one place.

100's of premium titles.
One news app.

Fortune

GLP-1s could end up being ‘the first true longevity drug’ as the world battles a rising obesity crisis

Top scientists from have suggested that GLP-1s could have broader effects than just tackling obesity and diabetes.

Benzinga

Eli Lilly To Rally More Than 12%? Here Are 10 Top Analyst Forecasts For Wednesday

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.

Fortune

Why big pharma is teaming up with AI giants to speed up drug discovery and make work easier for health care workers

Eli Lilly and J&J recently announced partnerships with AI chipmaker Nvidia, pointing to a broader trend of tie-ups to advance drug discovery and improve workflows.

Barchart

This Blue-Chip Stock Is a Heavy Weight in Weight-Loss Drugs

Eli Lilly (LLY) stands out for its diversified pharmaceutical portfolio, robust pipeline, and strategic acquisitions that are fueling growth. LLY has strong technical momentum and is trading at new all-time highs. Shares are up 43% over the past year. Analyst sentiment is overwhelmingly positive, with most major firms rating LLY...

Benzinga

Is AI The Key To Beating Cancer? Why Pharma Stocks Are Soaring

Something big is happening in healthcare, as pharma stocks have recently rallied on breakthrough AI developments that could reshape the entire industry.

The Guardian - UK

UK officials ‘working day and night’ to resolve NHS drug pricing row’

Patrick Vallance says government trying to rebuild relations with pharma industry as he outlines life sciences ambition

Benzinga

Eli Lilly Supremacy: How One Stock Is Dictating Performance Across Pharma ETFs

Eli Lilly And Co (NYSE:LLY) has officially become the giant quietly moving the strings behind a large slice of the pharma ETF universe. With blockbuster revenue growth, repeated earnings beats and a pipeline that refuses to slow down, Lilly isn’t just lifting its own stock – it’s powering a growing…

1 … 3 4 5 6

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.